Prolia or Ranmark Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of osteoporosis, rising incidence of bone metastases, aging global population, improved diagnosis of bone health disorders, wider clinical acceptance of biologic therapies.

The growth in the forecast period can be attributed to increasing demand for personalized bone therapies, rising investments in biologics manufacturing, growing focus on fracture prevention strategies, expansion of specialty clinic treatment models, increasing adoption of long-acting injectable drugs. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising focus on bone density preservation treatments, growing use of injectable osteoporosis drugs, expansion of long-term osteoporosis management protocols, enhanced monitoring of treatment adherence.

The increasing incidence of bone cancer is expected to drive the growth of the Prolia or Ranmark market moving forward. Bone cancer refers to a type of cancer that originates in the cells of the bones, which can be primary (starting in the bone) or secondary (spreading from other parts of the body). The rising incidence of bone cancer is attributed to factors such as genetic predisposition, exposure to radiation, and certain inherited conditions. Prolia or Xgeva (denosumab) helps in the management of bone cancer by inhibiting osteoclast activity, the cells responsible for bone resorption, thereby reducing the risk of bone fractures and slowing the progression of bone metastases in cancer patients. For example, in 2023, the American Cancer Society, a US-based professional organization, estimated that the number of new cancer cases for bones and joints increased to 3,970, up from 3,910 in 2022. Therefore, the rising incidence of bone cancer is contributing to the growth of the Prolia or Ranmark market.

Major companies in the Prolia or Ranmark market are focusing on developing technological advancements, such as interchangeable denosumab biosimilars, to enhance treatment accessibility, lower therapy costs, and maintain comparable safety and efficacy to the reference biologic. An interchangeable denosumab biosimilar is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting osteoclast-mediated bone resorption, and is formulated identically to Prolia, allowing substitution at the pharmacy level. For instance, in March 2024, Sandoz, a Switzerland-based biosimilars company, launched Jubbonti (denosumab-bbdz), an FDA-approved interchangeable biosimilar to Prolia. This product provides the same indications and dosing regimen as Prolia but is priced approximately 14% lower, improving patient access while maintaining clinical efficacy and safety.

In June 2024, Alvotech, a Luxembourg-based biotechnology company, expanded its strategic collaboration with Stada Arzneimittel AG to include a new biosimilar, AVT03, which is a proposed treatment for conditions such as osteoporosis and bone cancer, referencing Amgen's Prolia and Xgeva (denosumab). Stada Arzneimittel AG, a Germany-based pharmaceutical company, specializes in biosimilar products.

Major companies operating in the prolia or ranmark market are Amgen Inc., Daiichi Sankyo Co. Ltd.

North America was the largest region in the prolia or ranmark market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prolia or ranmark market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prolia or ranmark market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the prolia or ranmark market by increasing costs associated with imported biologic manufacturing equipment, cold-chain logistics infrastructure, specialized packaging materials, and raw monoclonal antibody inputs. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on cross-border biologics supply chains, while Asia-Pacific faces pricing pressure linked to import-based distribution. These tariffs contribute to higher treatment costs and reimbursement challenges. However, they are also encouraging localized biologics production, regional fill-finish capabilities, and supply chain diversification to enhance long-term market stability.

The prolia or ranmark market research report is one of a series of new reports that provides prolia or ranmark market statistics, including prolia or ranmark industry global market size, regional shares, competitors with a prolia or ranmark market share, detailed prolia or ranmark market segments, market trends and opportunities, and any further data you may need to thrive in the prolia or ranmark industry. This prolia or ranmark market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prolia, also known as Ranmark, is a prescription medication containing denosumab, which works by inhibiting RANKL to reduce bone resorption. By binding to RANKL, it prevents its interaction with osteoclasts, the cells responsible for breaking down bone tissue. This leads to increased bone density, strengthened bones, and a reduced risk of fractures. Prolia is used to treat osteoporosis and bone metastases in cancer patients.

The main indications for Prolia or Ranmark are osteoporosis and bone metastasis. Osteoporosis is a medical condition in which bones become weakened, raising the risk of fractures, particularly in older adults and postmenopausal women. Prolia is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by a wide range of end users, such as hospitals, specialty clinics, homecare providers, and ambulatory surgical centers.

The prolia or ranmark market consists of sales of prolia subcutaneous injections, 60 mg and 120 mg and ranmark subcutaneous injection 120 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.